cystetic Medicines, Inc.

American biotechnology company at Boston in Massachusetts, founded in 2020 on work by Martin Burke of the University of Illinois and Michael Welsh of the University of Iowa. Develops inhaled small molecules described as molecular prosthetics, built on amphotericin B, which form ion channels in airway cells to restore salt and water transport in cystic fibrosis, aimed at the patients who make little or no CFTR protein and gain nothing from modulator drugs; its lead candidate CM001 entered phase 1 trials in 2023.